The Acne Landscape Is Evolving

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Background

Treatment for Acne Is Growing

Psychosocial and QoL Impact of Patients With Acne

Severity of Acne and Impact on Patients

Determining Acne Severity

Guideline Recommended Treatments for Moderate to Severe Acne

Individualizing Treatment for Patients With Moderate to Severe Acne

Tips to Increase Adherence to Acne Treatment

New Topical Retinoid Tretinoin 0.05% Lotion

Evaluating Patient Satisfaction

Results Tretinoin 0.05% Lotion

Relevance to Clinical Practice

New Topical Antibiotic 4% Minocycline Foam

Efficacy 4% Minocycline Foam Absolute Change in Inflammatory Lesion Count at Week 12

Efficacy 4% Minocycline Foam Proportion of Patients Achieving IGA = Clear/Almost Clear

Safety Minocycline 4% Foam

New Retinoid With a New MOA Trifarotene 50 μg/g Cream

PERFECT 1 and 2 Efficacy Endpoints Trifarotene 50 μg/g Cream

Results: Facial IGA and Truncal PGA Trifarotene 50 μg/g Cream

Safety Trifarotene 50 μg/g Cream

New Topical Anti-Androgen Clascoterone 1% Cream

Phase 3 Baseline Lesion Counts & IGA Scores Clascoterone 1% Cream

Phase 3 Efficacy Results Clascoterone 1% Cream

Clascoterone, 1% Cream Acne Phase 3 Studies IGA Treatment Success at Week 12: IGA (0) or (1)

Clascoterone, 1% Cream: Phase 3 Studies Absolute Reduction of Non-Inflammatory Lesion Count Week 12

New Oral Antibiotic Sarecycline

Phase 3 Study Design Sarecycline

Efficacy Sarecycline

Safety Sarecycline

Which Patients Are Good Candidates for These Medications?

Concluding Remarks

Abbreviations